StockNews.com began coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Free Report) in a report released on Saturday morning. The brokerage issued a sell rating on the stock.
Separately, Maxim Group cut their price target on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th.
Check Out Our Latest Report on MBRX
Moleculin Biotech Stock Performance
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Recommended Stories
- Five stocks we like better than Moleculin Biotech
- Buy P&G Now, Before It Sets A New All-Time High
- How to Invest in Small Cap Stocks
- How to Calculate Retirement Income: MarketBeat’s Calculator
- These Are the Dividend Stocks Insiders Bought in January
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
